Endocarditis associated with the lead of an implantable cardioverter-defibrillator

    Authors

    Keywords

    infective endocarditis, cardioverter-defibrillator, enterococcal sepsis

    DOI

    https://doi.org/10.15836/ccar2024.583

    Full Text

    **Introduction**: Infective endocarditis is a serious medical condition associated with high mortality and morbidity, despite advancements in diagnosis and treatment. With the aging population, the increasing use of cardiac implantable electronical devices and heart valves, the risk of infective endocarditis, has grown significantly over the years with its incidence on the rise. (1) This paper presents the case of a 54-year-old patient with enterococcal endocarditis linked to cardioverter, defibrillator leads and surgically treated tricuspid and mitral valves. **Case report**: The patient presented with symptoms such as high fever and back pain and was treated with antibiotics a long side surgical removal of the device. His symptoms included a fever reaching up to 40°C persisting for three weeks. He was evaluated at an infectious disease clinic where Enterococcus faecalis was isolated in three sets of blood cultures. Initially treated for enterococcal sepsis with suspected endocarditis at the infectious clinic. The patient was later transferred to Dubrava University Hospital for further treatment. Transesophageal echocardiography revealed vegetation on the lead of the implantable cardioverter-defibrillator (ICD), and treatment proceeded with three intravenous antibiotics. The patient’s medical history includes the implantation of a mechanical mitral valve and tricuspid valve annuloplasty with a ring in 2022. He also had a ICD implanted in 2015, which was replaced in 2022. The patient underwent a six-week course of antibiotic therapy, during which complete extraction of the ICD and leads was performed. How ever, due to secondary prevention after two weeks of stable inflammatory markers and an echocardiogram showing no visible vegetations, a subcutaneous ICD was implanted to mitigate the risk of sudden cardiac death. The S-ICD was developed as an alternative for patients without venous access to the heart, aiming to reduce complications such as endocarditis associated with transvenous leads. (2) The patient was discharged after 42 days of treatment in improved general condition, with regular follow-ups by a cardiologist and device check-ups. **Conclusion**: In patients with cardiac implantable electronic devices and prosthetic valves, a multidisciplinary approach involving surgical intervention, targeted antibiotic therapy, and alternative device strategies, such as the use of an S-ICD, can be critical in managing infection risks and improving outcomes in cases of infective endocarditis.

    Literature

    1. Budea CM, Bratosin F, Bogdan I, Bota AV, Turaiche M, Tirnea L, et al. Clinical Presentation and Risk Factors of Infective Endocarditis in the Elderly: A Systematic Review. J Pers Med. 2023 February 7;13(2):296. https://doi.org/10.3390/jpm13020296
    2. van Dijk VF, Boersma LVA. Non-transvenous ICD therapy: current status and beyond. Herz. 2021 December;46(6):520–5. https://doi.org/10.1007/s00059-021-05077-4
    Cardiologia Croatica
    Back to search

    Endocarditis associated with the lead of an implantable cardioverter-defibrillator

    Extended Abstract
    Issue11-12
    Published
    Pages583
    PDF via DOIhttps://doi.org/10.15836/ccar2024.583
    infective endocarditis
    cardioverter-defibrillator
    enterococcal sepsis

    Authors

    Josipa Pekez*ORCIDDubrava University Hospital, Zagreb, Croatia
    Ivana ŠmucORCIDDubrava University Hospital, Zagreb, Croatia
    Zrinka PaićORCIDDubrava University Hospital, Zagreb, Croatia
    Ivica BenkoORCIDDubrava University Hospital, Zagreb, Croatia
    Nikolina ValjakORCIDDubrava University Hospital, Zagreb, Croatia
    Ivana AlkovićORCIDDubrava University Hospital, Zagreb, Croatia
    Dora AldžićORCIDDubrava University Hospital, Zagreb, Croatia
    Valentina BrckovićORCIDDubrava University Hospital, Zagreb, Croatia
    Kristina Kardum AntunovićORCIDDubrava University Hospital, Zagreb, Croatia
    Petra OzimecORCIDDubrava University Hospital, Zagreb, Croatia
    Julija BuljanORCIDDubrava University Hospital, Zagreb, Croatia
    Anita PleškoORCIDDubrava University Hospital, Zagreb, Croatia
    Anamarija MikšaORCIDDubrava University Hospital, Zagreb, Croatia
    Ljiljana BažantORCIDDubrava University Hospital, Zagreb, Croatia

    *Correspondence email: joshiiii2000@gmail.com

    Full Text

    Introduction: Infective endocarditis is a serious medical condition associated with high mortality and morbidity, despite advancements in diagnosis and treatment. With the aging population, the increasing use of cardiac implantable electronical devices and heart valves, the risk of infective endocarditis, has grown significantly over the years with its incidence on the rise. (1) This paper presents the case of a 54-year-old patient with enterococcal endocarditis linked to cardioverter, defibrillator leads and surgically treated tricuspid and mitral valves.

    Case report: The patient presented with symptoms such as high fever and back pain and was treated with antibiotics a long side surgical removal of the device. His symptoms included a fever reaching up to 40°C persisting for three weeks. He was evaluated at an infectious disease clinic where Enterococcus faecalis was isolated in three sets of blood cultures. Initially treated for enterococcal sepsis with suspected endocarditis at the infectious clinic. The patient was later transferred to Dubrava University Hospital for further treatment. Transesophageal echocardiography revealed vegetation on the lead of the implantable cardioverter-defibrillator (ICD), and treatment proceeded with three intravenous antibiotics. The patient’s medical history includes the implantation of a mechanical mitral valve and tricuspid valve annuloplasty with a ring in 2022. He also had a ICD implanted in 2015, which was replaced in 2022. The patient underwent a six-week course of antibiotic therapy, during which complete extraction of the ICD and leads was performed. How ever, due to secondary prevention after two weeks of stable inflammatory markers and an echocardiogram showing no visible vegetations, a subcutaneous ICD was implanted to mitigate the risk of sudden cardiac death. The S-ICD was developed as an alternative for patients without venous access to the heart, aiming to reduce complications such as endocarditis associated with transvenous leads. (2) The patient was discharged after 42 days of treatment in improved general condition, with regular follow-ups by a cardiologist and device check-ups.

    Conclusion: In patients with cardiac implantable electronic devices and prosthetic valves, a multidisciplinary approach involving surgical intervention, targeted antibiotic therapy, and alternative device strategies, such as the use of an S-ICD, can be critical in managing infection risks and improving outcomes in cases of infective endocarditis.

    Literature

    1. 1.
      Budea CM, Bratosin F, Bogdan I, Bota AV, Turaiche M, Tirnea L, et al. Clinical Presentation and Risk Factors of Infective Endocarditis in the Elderly: A Systematic Review. J Pers Med. 2023 February 7;13(2):296.DOI
    2. 2.
      van Dijk VF, Boersma LVA. Non-transvenous ICD therapy: current status and beyond. Herz. 2021 December;46(6):520–5.DOI